- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04285099
Frequency Effect of STN-DBS Through the Dual System on FOG in PD
February 24, 2020 updated by: BS Jeon, Seoul National University Hospital
Frequency Effect of Subthalamic Nucleus Deep Brain Stimulation Through the Dual System on Freezing of Gait in Parkinson Disease
We aim to confirm the effect for FOG by changing the frequency through the dual-system approach in PD patients after STN-DBS.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
The investigators set two values of frequency (130, 60Hz) in IPG and allow the patients to change the frequencies freely using the patient controller.
After four weeks, the investigators will check the UPDRS part I, II, IV, FOG-Q, and PDQ-39 values at each frequency, including the proportion of use of two frequencies.
Study Type
Interventional
Enrollment (Anticipated)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of
- Beom S Jeon
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
30 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- patients with PD who are aged 30 years or older
- patients with bilateral STN-DBS
- patients who have a FOG at their med "off" state in outpatient clinic or hospitalization, or UPDRS part II FOG subscore above 1
Exclusion Criteria:
- patients without FOG
- patients who have undergone DBS
- patients who have had previous brain surgery
- patients who have undergone reoperation of DBS
- patients who underwent unilateral DBS
- patients with cognitive impairment (MMSE <18)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: PD patients with FOG after STN-DBS[A]
Initially started by A setting
|
The investigators set two values of frequency (130, 60Hz) in IPG and allow the patients to change the frequencies freely using the patient controller.
Technician randomly sets 130 Hz, 60HZ to A or B.
|
|
Experimental: PD patients with FOG after STN-DBS[B]
Initially started by B setting
|
The investigators set two values of frequency (130, 60Hz) in IPG and allow the patients to change the frequencies freely using the patient controller.
Technician randomly sets 130 Hz, 60HZ to A or B.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Stimulation frequency ratio in 4 weeks
Time Frame: 4 weeks
|
Proportion of two frequencies in 4 weeks
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Comparison of Movement Disorder Society Unified Parkinson's Disease Rating Scale Part I score in 130 and 60Hz at the fourth week
Time Frame: 4 weeks
|
Movement Disorder Society Unified Parkinson's Disease Rating Scale Part I score will be used to compare 130Hz with 60Hz.
Higher scores mean a worse outcome.
[minimum 0, maximum 52]
|
4 weeks
|
|
Comparison of Movement Disorder Society Unified Parkinson's Disease Rating Scale Part II score in 130 and 60Hz at the fourth week
Time Frame: 4 weeks
|
Movement Disorder Society Unified Parkinson's Disease Rating Scale Part II score will be used to compare 130Hz with 60Hz.
Higher scores mean a worse outcome.
[minimum 0, maximum 52]
|
4 weeks
|
|
Comparison of Movement Disorder Society Unified Parkinson's Disease Rating Scale Part IV score in 130 and 60Hz at the fourth week
Time Frame: 4 weeks
|
Movement Disorder Society Unified Parkinson's Disease Rating Scale Part IV score will be used to compare 130Hz with 60Hz.
Higher scores mean a worse outcome.
[minimum 0, maximum 24]
|
4 weeks
|
|
Comparison of Freezing of Gait Questionnaire score in 130 and 60Hz at the fourth week
Time Frame: 4 weeks
|
Freezing of Gait Questionnaire score will be used to compare 130Hz with 60Hz.
Higher scores mean a worse outcome.
[minimum 0, maximum 24]
|
4 weeks
|
|
Comparison of Parkinson's Disease Questionnaire-39 score in 130 and 60Hz at the fourth week
Time Frame: 4 weeks
|
Parkinson's Disease Questionnaire-39 score will be used to compare 130Hz with 60Hz.
Higher scores mean a worse outcome.
[minimum 0, maximum 156]
|
4 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
March 1, 2020
Primary Completion (Anticipated)
February 28, 2021
Study Completion (Anticipated)
February 28, 2021
Study Registration Dates
First Submitted
February 24, 2020
First Submitted That Met QC Criteria
February 24, 2020
First Posted (Actual)
February 26, 2020
Study Record Updates
Last Update Posted (Actual)
February 26, 2020
Last Update Submitted That Met QC Criteria
February 24, 2020
Last Verified
February 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- H-1902-132-1091
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
Bezmialem Vakif UniversityRecruitingParkinson Disease | Parkinson | Parkinson Disease (PD) | PARKINSON DISEASE (Disorder) | Parkinson s DiseaseTurkey (Türkiye)
-
CND Life SciencesDigestive Disease Associates of CTRecruitingParkinson Disease | Parkinson | PARKINSON DISEASE (Disorder) | Parkinson s DiseaseUnited States
-
Neuron23 Inc.Roche Diagnostic Ltd.; Qiagen Manchester LimitedRecruitingParkinson Disease | Parkinson | Idiopathic Parkinson Disease | Parkinson Disease, Idiopathic | Early Parkinson Disease (Early PD)United States, Spain, Israel, Poland, Italy, United Kingdom
-
San Francisco Neurology and Sleep CenterNot yet recruitingPARKINSON DISEASE (Disorder) | Parkinson s DiseaseUnited States
-
Haukeland University HospitalUniversity of Bergen; SPARK NSRecruitingParkinson Disease (PD) | Parkinson s DiseaseNorway
-
CND Life SciencesOregon Health and Science UniversityRecruitingParkinson Disease | Parkinson | Parkinson's Disease and Parkinsonism | PARKINSON DISEASE (Disorder)United States
-
Università degli Studi dell'InsubriaUniversidade Nova de Lisboa; Associazione Parkinson Insubria (AsPI), Section... and other collaboratorsRecruitingParkinson Disease | Parkinson | Parkinson Disease, Idiopathic | PARKINSON DISEASE (Disorder)Italy
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
Duke UniversityMedical University of South Carolina; Massachusetts General Hospital; Mayo Clinic and other collaboratorsNot yet recruitingGut Microbiota | Gut Microbiome | Parkinson Disease (PD) | PARKINSON DISEASE (Disorder) | Prodromal Parkinsons DiseaseUnited States
-
ProgenaBiomeWithdrawnParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
Clinical Trials on Application of dual system in frequency A
-
University of California, Los AngelesNational Institutes of Health (NIH)CompletedEpilepsy | Sudden Cardiac DeathUnited States
-
Hospital Central de la Defensa Gómez UllaUnknownIntravascular Catheter ColonizationSpain
-
University of UlmRecruitingCOVID-19 | Critical Illness | Lung Fibrosis | HypercytokinemiaGermany
-
Inonu UniversityCompletedUniversity StudentsTurkey
-
Centre Hospitalier Universitaire de BesanconNot yet recruiting
-
University of Castilla-La ManchaCompleted
-
Weill Medical College of Cornell UniversityIthaca CollegeNot yet recruitingTransitioning Voice of Transgender and Gender Diverse PeopleUnited States
-
Universidad de GranadaAmgen; Fundación Pública Andaluza para la Investigación Biomédica Andalucía... and other collaboratorsNot yet recruiting
-
Somerville Office of Emergency ManagementCompletedHemorrhageUnited States
-
BackBeat Medical IncCompleted